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Abstract
Introduction: Systemic sclerosis (SSc) is an autoimmune inflammatory disorder of unknown etiology characterized
by fibrosis of the skin and internal organs. Ang II (angiotensin II), a vasoconstrictive peptide, is a well-known
inducer of kidney, heart, and liver fibrosis. The goal of this study was to investigate the profibrotic potential of Ang
II in the mouse skin.
Methods: Ang II was administered by subcutaneous osmotic mini pumps to C57BL/6 male mice. Collagen-content
measurements were performed with Gomori Trichrome staining and hydroxyproline assay. The mRNA expression
level of collagens, TGF-b1, TGF-b2, TGF-b3, CTGF, aSMA, CD3, Emr1, CD45/B220, MCP1, and FSP1 were quantified with
real-time polymerase chain reaction (PCR). Immunostaining was performed for markers of inflammation and
fibrosis, including, phospho-Smad2, aSMA, CD3, Mac3, CD45/B220, and CD163B. Fibrocytes were identified by
double staining with CD45/FSP1 and CD45/PH4. Endothelial cells undergoing endothelial-to-mesenchymal
transition (EndoMT) were identified by double staining with VE-cadherin/FSP1.
Results: Ang II-infused mice develop prominent dermal fibrosis in the area proximal to the pump, as shown by
increased collagen and CTGF mRNA levels, increased hydroxyproline content, and more tightly packed collagen
fibers. In addition, elevated mRNA levels of TGF-b2 and TGF-b3 along with increased expression of pSmad2 were
observed in the skin of Ang II-treated mice. Dermal fibrosis was accompanied by an increased number of
infiltrating fibrocytes, and an increased number of aSMA-positive cells, as well as CD163B+ macrophages in the
upper dermis. This correlated with significantly increased mRNA levels of aSMA, Emr1, and MCP1. Infiltration of
CD3-, CD45/B220-, and Mac3-positive cells was observed mainly in the hypodermis. Furthermore, an increased
number of double-positive VE-cadherin/FSP1 cells were detected in the hypodermis only.
Conclusions: This work demonstrates that Ang II induces both inflammation and fibrosis in the skin via MCP1
upregulation and accumulation of activated fibroblasts. Additionally, our data suggest that populations of these
fibroblasts originate from circulating blood cells. Ang II infusion via osmotic minipumps could serve as a useful
mouse model of skin fibrosis to gain new insights into pathogenic mechanisms and to test new antifibrotic
therapies.
Introduction
Systemic sclerosis (SSc) is a complex autoimmune
inflammatory disorder of unknown etiology characterized
by vascular alterations, activation of the immune system,
and fibrosis of the skin and internal organs [1]. Vascular
insufficiency and immune dysfunction manifest early in
the disease and are followed by increased extracellular
matrix (ECM) production as the disease progresses.
Raynaud phenomenon (RP) is present in the majority of
SSc patients and can precede definite diagnosis of SSc by
years or even decades. In patients with SSc, RP is asso-
ciated with structural abnormalities of the microvascula-
ture and the presence of SSc-specific autoantibodies [2],
indicating an early link between immune system activa-
tion and vascular injury. Fibrosis results from excessive
production and accumulation of ECM components pro-
duced by activated fibroblasts, which might be triggered
by cytokines and growth factors released from the infil-
trating immune cells during the inflammatory stage [3].
However, interrelations between the key pathologic com-
ponents of the disease are still poorly understood.
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Angiotensin II (Ang II), a main component of the
rennin-angiotensin system (RAS), is a vasoactive peptide
that induces vascular constriction, salt and water reten-
tion, and increased blood pressure [4]. Ang II has been
reported to play a critical role in renal and heart fibrosis
through inflammation and upregulation of matrix deposi-
tion [5,6]. Previous studies also suggest that Ang II may
be involved in the pathogenesis of skin fibrosis in SSc. It
has been shown that Ang II levels are increased in the
blood of SSc patients and that, in contrast to healthy
skin, the Ang II precursor angiotensinogen is expressed
in SSc skin [7]. Furthermore, the profibrotic effects of
Ang II are mediated via the AT1a receptor in cultured
human and mouse skin fibroblasts [8]. In addition, dysre-
gulation of RAS components was shown in patients with
SSc, with a prevalence of the vasoconstricting Ang II
over the vasodilating Ang-(1-7), suggesting inhibition of
endothelium-dependent vasodilatation and increased
vasoconstriction in SSc vessels [9].
Utilization of animal models has been instrumental in
delineating complex pathologic features of SSc. In the last
decade, a number of new animal models became available
to study mechanisms of SSc fibrosis [10-13]. The inducible
models of SSc include the widely studied bleomycin and
more recently established hypochlorous acid (HOCH)
injection models, as well as the immune-based scleroder-
matous graft-versus-host model. A growing number of
genetic models are very valuable for investigating specific
signaling pathways involved in fibrosis [14,15]. Whereas
none of the currently available models recapitulate the
complex features of SSc, they provide important insights
into selected aspects of SSc pathogenesis and allow precli-
nical testing of antifibrotic compounds.
Angiotensin II has been widely used to investigate kidney
[5], heart [6], and liver [16] fibrosis by using mouse models.
However, the profibrotic potential of Ang II has not been
evaluated in any model of dermal fibrosis. Given the poten-
tial involvement of Ang II in the pathogenesis of SSc, the
goal of this study was to investigate the effect of Ang II on
dermal fibrosis in a mouse model.
Materials and methods
Subcutaneous infusion of angiotensin II using ALZET
osmotic minipumps
C57BL/6 mice were purchased from The Jackson Labora-
tory. All of the experiments were performed under the
guidelines of the Boston University Institutional Animal
Care and Use Committee (protocol AN-15037). Alzet
osmotic miniature pumps (model 2002) delivering angio-
tensin II (Sigma-Aldrich, St. Louis, MO, USA) at a rate of
1,000 ng/kg/min (pressor dose) or 2,000 ng/kg/min, or
PBS, were implanted subcutaneously on the backs of
8-week-old mice. After 14 days, mice were killed, and the
skin surrounding the pump outlet was collected by using
an 8-mm-diameter punch biopsy device.
Gomori Trichrome staining
Gomori Trichrome staining was used to detect collagen
fibers and collagen deposition in the mouse skin. The skin
samples were fixed in 4% paraformaldehyde for 24 hours
and then processed for paraffin embedding. Staining was
performed on 8-μm-thick paraffin sections by following
the manufacturer’s instructions (Chromaview, Dublin,
OH, USA; Gomori Trichrome blue collagen Kit S7440-
19). Collagen fibers were stained blue, nuclei were stained
black, and the background was stained red.
Hydroxyproline assay
Collagen deposition was quantified by measuring total
hydroxyproline content in 4-mm skin-punch biopsies
obtained from PBS and Ang II infusion sites by using a pre-
viously described method with some modifications [17]. In
brief, the skin samples were hydrolyzed with 6 M sodium
hydroxide at 110°C for 12 hours. The hydrolyzate was then
oxidized with oxidation buffer (one part 7% chloramine T
and four parts of acetate citrate buffer) for 4 minutes at
room temperature. Ehrlich aldehyde reagent was added to
each sample, and the chromophore was developed by incu-
bating the samples at 65°C for 25 minutes. Absorbance of
each sample was read at 560 nm by using a spectro-
phometer. Results were expressed as total hydroxyproline
content (in micrograms) per 0.1 g of tissue. A standard
curve was performed for all hydroxyproline measurements
by using known quantities of hydroxyproline.
Quantitative RT-PCR analysis
Total RNA was isolated by using the RNeasy Fibrous Tis-
sue Mini Kit (Qiagen, Valencia, CA, USA). Then, 1 μg of
total RNA was reverse transcribed with random hexam-
ers by using the Transcriptor First Strand Complemen-
tary DNA Synthesis kit (Roche Applied Science,
Indianapolis, IN, USA) according to the manufacturer’s
protocol. Real-time PCR assays were performed by using
the StepOnePlus Real-Time PCR system (Applied Biosys-
tems, Foster City, CA, USA). The amplification mixture
(10 μl) contained 1 μl of complementary DNA, 0.5 μM of
each primer, and 5 μl of SYBR Green PCR Master Mix.
The primers are listed in Supplementary Table 1. Relative
change in the levels of genes of interest was determined
by the 2-ΔΔCT method.
Immunofluorescence staining on frozen sections
For all immunofluorescence staining, skin samples were
directly embedded in O.C.T. compound, flash frozen,
and stored at -80°C. Staining was performed on 8-μm
cryosections of mouse skin. In brief, slides were blocked
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with a blocking solution (3% BSA (Sigma-Aldrich), and
0.3% Triton X-100 in PBS) for 2 hours. After washing,
tissue sections were incubated at 4°C overnight with pri-
mary antibodies (Table 2). Tissue sections were then
washed and incubated with secondary Ab (Table 2) at
room temperature for 2 hours. Coverslips were mounted
by using Vectashield with DAPI (Vector Laboratories,
Burlingame, CA, USA), and staining was examined by
using a FluoView FV10i confocal microscope system
(Olympus, Center Valley, PA, USA) at 488 nm (green),
594 nm (red), and 405 nm (blue).
Immunofluorescence staining on adherent cell cultures
Human dermal microvascular endothelial cells (HDMECs)
were isolated from human foreskin, as previously
described [18]. Cells were cultured on bovine collagen-
coated six-well plates in EBM medium supplemented with
10% FBS and EC growth supplement mix at 37°C with 5%
CO2 in air. The culture medium was changed every other
day. For immunofluorescence, cultured HDMECs grown
on collagen-coated coverslips were treated with Ang II
(1,000 ng/ml) for 96 hours. Control and Ang II-treated
cells were fixed with 4% paraformaldehyde for 15 minutes
followed by incubation with 0.15 M glycine for 30 min-
utes. Nonspecific protein binding was blocked with 3%
BSA for 1 hour. Next, cells were incubated at 4°C over-
night with primary antibodies: goat anti-mouse VE-cad-
herin (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
and rabbit anti-mouse FSP1 (Abcam, Cambridge, MA,
USA). After washing, cell cultures were incubated with
Alexa fluor 488 donkey anti-goat (Invitrogen, Grand
Island, NY, USA) and Alexa fluor 594 donkey anti-rabbit
(Invitrogen) antibodies for 1.5 hour. Cells were mounted
on slides by using Vectashield with DAPI (Vector Labora-
tories) and examined by using a FluoView FV10i confocal
microscope system (Olympus, Center Valley, PA, USA) at
488 nm (green), 594 nm (red), and 405 nm (blue).
Immunohistochemistry
Immunohistochemistry was performed on formalin-
fixed, paraffin-embedded skin tissue sections by using
the Vectastain ABC kit (Vector Laboratories) according
to the manufacturer’s instructions. In brief, sections (8-
μm thick) were mounted on APES (aminopropyl-
triethoxy silane solution)-coated slides, deparaffinized
with Histo-Clear (National Diagnostics, Atlanta, GA,
USA), and rehydrated through a graded series of etha-
nol. Endogenous peroxidase was blocked by incubation
in 3% hydrogen peroxide for 30 minutes, followed by
incubation with 0.15 M glycine for 45 minutes, and nor-
mal blocking serum for 1 hour. The sections were then
incubated overnight at 4°C with antibodies against CD3
(Abcam, Cambridge, MA, USA), Mac3 (BD Bioscience,
San Jose, CA, USA), CD45R (AbD Serotec, Raleigh, NC,
USA), or CD163B (Epitomics, Burlingame, CA, USA),
diluted 1:100 in blocking buffer, followed by incubation
for 30 minutes with a biotinylated secondary antibody
solution. A solution containing avidin:biotin:peroxidase
complexes was applied to the sections subsequently.
Immunoreactivity was visualized with diaminobenzidine
(Vector Laboratories), and the sections were counter-
stained with hematoxylin. Images were collected by
using a microscope (BH-2; Olympus, Center Valley, PA,
USA).
Statistical analyses
All data were analyzed with the Student paired t test.
The level for statistical significance was set at P ≤
0.05.
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Results
Angiotensin II increases collagen synthesis and
deposition in mouse skin
To determine whether angiotensin II can induce dermal
fibrosis, Ang II at a rate of 1,000 ng/kg/min was adminis-
tered continuously with subcutaneous osmotic minipumps
implanted under the shaved back skin of 8-week-old
C57BL/6 male mice. Treated skin was harvested at day 14,
and histologic examination and collagen-content measure-
ment assays were performed. Gomori Trichrome staining
showed that collagen fibers were more closely packed in
angiotensin II-treated mice compared with control mice,
reflecting increased collagen deposition (Figure 1A). In
addition, the fat layer of the reticular dermis was partially
replaced with extracellular matrix (Figure 1A). Real-time
PCR analysis showed a statistically significant increase in
mRNA levels of the collagen-encoding genes: Col1a1,
Col1a2, Col3a1, and Col5a1, as well as CTGF (2.4-fold,
1.9-fold, and 3.4-fold, 1.9-fold, and 2.1-fold, respectively;
*P ≤ 0.05) in the skin of Ang II-infused mice when com-
pared with control mice (Figure 1B). Total hydroxyproline
content from the injected sites was significantly higher in
Ang II (1,000 ng/kg/min)-infused skin (2,481 ± 920 μg per
0.1 g of skin) compared with control PBS-infused skin
(1,534 ± 430 μg per 0.1 g of skin; *P ≤ 0.05) (Figure 1C).
A higher dose of Ang II (2,000 ng/kg/min) showed a larger
Table 2 Primary and secondary antibodies for immunofluorescence staining
Primary antibodies Secondary antibodies
Myofibroblasts Rabbit anti-mouse aSMA Ab (Novus Biologicals, Littleton, CO); 1:100 Alexa fluor 488 donkey anti-rabbit IgG (Invitrogen, Grand
Island, NY); 1:1,000
Fibrocytes Rat anti-mouse CD45 Ab (BD
Pharmingen, San Diego, CA); 1:50
Rabbit anti-mouse FSP1 Ab
(Abcam, Cambridge, MA);
1:100
Alexa fluor 594 donkey anti-
rat IgG (Invitrogen); 1:1,000
Alexa fluor 488 donkey anti-
rabbit IgG (Invitrogen);
1:1,000
EndoMT Goat anti-mouse VE-cadherin Ab (Santa
Cruz Biotechnology, Santa Cruz, CA);
1:300
Rabbit anti-mouse FSP1 Ab
(Abcam); 1:100
Alexa fluor 488 donkey anti-
goat IgG (Invitrogen);
1:1,000
Alexa fluor 594 donkey anti-
rabbit IgG (Invitrogen);
1:1,000
Figure 1 Angiotensin II increases collagen synthesis and deposition in mouse skin. (A) Gomori Trichrome staining shows a histologic
evaluation of Ang II-induced lesions in C57BL/6 mice. (B) Real-time PCR analysis of collagen-encoding genes: Col1a1, Col1a2, Col3a1, Col5a1,
along with CTGF (*P ≤ 0.05) in PBS-and Ang II-treated mice. (C) Total hydroxyproline content in PBS- and Ang II-treated mice. Values are the
mean of six mice in each group; *P ≤ 0.05.
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increase in the total hydroxyproline content of local skin
(5,272 ± 1,260 μg per 0.1 g of Ang II-infused skin versus
1,748 ± 531 μg per 0.1 g of PBS-infused skin; *P ≤ 0.05)
(Figure 1C). The profibrotic effects of Ang II were local, as
no significant differences were observed in hydroxyproline
content in distal skin with either concentration of Ang II
(data not shown). Because a dose of 1,000 ng/kg/min was
sufficient to induce significant dermal fibrosis, this dose
was selected for further analyses.
Angiotensin II activates the TGF-b pathway in mouse skin
Transforming growth factor-b (TGF-b) plays a pivotal role
in the pathogenesis of scleroderma by activating fibroblasts
and stimulating the production of ECM components [19].
To determine whether Ang II treatment activates the
TGF-b pathway, we examined skin samples from the
infused sites with real-time PCR and immunostaining.
Real-time PCR analysis showed statistically significant
increases in the mRNA levels of TGF-b2 and TGF-b3 (3.2-
fold and 4.8-fold, respectively; *P ≤ 0.05) in Ang II-treated
mouse skin (Figure 2A). No differences were observed in
the mRNA expression of TGF-b1 (Figure 2A). Immuno-
histochemical staining of pSmad2 was performed on par-
affin sections. We observed increased numbers of
pSmad2-positive cells distributed throughout all dermal
layers in Ang II-treated mice (Figure 2B). These data sug-
gest that Ang II potently activates TGF-b signaling in this
model.
Angiotensin II increases the number of myofibroblasts in
mouse skin
Fibrosis is associated with accumulation of activated
fibroblasts/myofibroblasts in the affected tissues. To
determine whether Ang II treatment increases myofibro-
blast presence, skin from infused sites was examined with
real-time PCR and immunostaining for aSMA. Real-time
PCR analysis showed a statistically significant increase in
the mRNA level of aSMA (1.9-fold, *P ≤ 0.05) in Ang II-
treated mouse skin (Figure 3A). aSMA staining was per-
formed on cryosections (immunofluorescence, Figure 3B
and 3D) and paraffin sections (immunohistochemistry,
Figure 3C) from PBS- and Ang II-treated mouse skin.
Figure 2 Angiotensin II activates TGF-b signaling. (A) Real-time PCR analysis of TGF-b1, TGF-b2, and TGF-b3 (*P ≤ 0.05) in PBS- and Ang II-
treated mice. (B) pSmad2 staining on paraffin sections from PBS- and Ang II-infused mice. Representative images are shown from four animals
per group.
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Affected sites from PBS-treated mice contained few
aSMA-positive cells, observed exclusively around the
blood vessels and the arrector pili muscles. In contrast,
affected sites from Ang II-treated mice showed an
increased number of cells expressing aSMA distributed
mainly throughout the upper dermis (Figure 3B and 3C),
whereas in the lower dermis, positive cells were observed
only around the blood vessels (Figure 3D). These data
suggest that Ang II-induced myofibroblast differentiation
contributes to the development of fibrosis in this model.
Angiotensin II increases inflammation in mouse skin
Previous studies have shown that Ang II promotes
inflammation in kidney and heart models of fibrosis [5,6].
To evaluate the recruitment of inflammatory cells, skin
samples from the Ang II-infused sites were examined
with real-time PCR and immunostaining of immune cell
markers. Real-time PCR analysis showed statistically sig-
nificant increases in the mRNA levels of the T-cell mar-
ker, CD3, B-cell marker, CD45/B220, and the
macrophage marker Emr1 (2.0-fold, 3.4-fold, and 3.6-
fold, respectively; *P ≤ 0.05), in Ang II-treated mouse
skin (Figure 4A and 5A). Immunohistochemical staining
of CD3, CD45R, and two macrophage markers, a general
marker, Mac3 [20], and a marker identifying M2 macro-
phages, CD163B [21,22] was performed on paraffin sec-
tions. We observed increased infiltration of CD3, CD45R,
and Mac3-positive cells only in the hypodermis of Ang
II-treated mice (Figure 4B and 5B). Interestingly, we
observed an increased presence of CD163B-positive cells
in the upper dermis of Ang II-treated mice, whereas no
increase was found in the lower dermis or hypodermis
(Figure 5C).
Angiotensin II increases infiltration of fibrocytes in the
upper dermis
Circulating mesenchymal cells, fibrocytes, have been
shown to infiltrate areas of inflammation and tissue
damage and contribute to the fibrotic process [23]. To
determine whether fibrocytes are involved in the dermal
fibrosis induced by Ang II, skin cryosections were stained
for the immune cell marker, CD45, and mesenchymal
markers, FSP1 and P4H. Skin samples from the Ang II-
injected mice showed increased numbers of the CD45/
FSP1 double-positive cells (3.83% ± 0.49% versus 0.94% ±
0.37% of total number of cells/HPF; *P ≤ 0.05) distributed
Figure 3 Detection of activated fibroblasts in angiotensin II-treated skin. (A) Real-time PCR analysis of aSMA in PBS- and Ang II-treated
mice (*P ≤ 0.05). aSMA staining in the upper dermis (B) by immunofluorescence and (C) by immunohistochemistry, and in the lower dermis
(D) by immunofluorescence, on sections from PBS- and Ang II-treated mouse skin. Arrows indicate positive staining of myofibroblasts.
Representative images are shown from five animals per group.
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mostly around small vessels in the lower dermis and
around the sclerotic collagen bundles in the upper dermis
(Figure 6A). Similar results were observed for the CD45/
P4H double-positive cells (5.11% ± 0.6% versus 2.85% ±
0.75% of cells per HPF; *P ≤ 0.05; Figure 6A). In addition,
although only a few FSP1-positive cells were seen in PBS-
infused skin, a significant increase in FSP1 cells was
observed in the upper dermis of Ang II-infused mice
(Figure 6A). We also observed a 1.55-fold increase in
FSP1 mRNA levels in circulating cells isolated from Ang
II-treated mice; however, this difference was not statisti-
cally significant (data not shown). However, mRNA levels
of FSP1 and of the inflammatory chemokine MCP1, a
chemoattractant for fibrocytes, were significantly elevated
(1.94-fold, 2.5-fold, respectively; *P < 0.05) in Ang II-trea-
ted mouse skin (Figure 6B). No differences were observed
in the mRNA expression of another fibrocyte chemoat-
tractant, SDF1/CXCL12 (data not shown).
Angiotensin II increases endothelial-to-mesenchymal
transition
Recent studies have indicated that EndoMT can contri-
bute to the progression of fibrotic diseases, and Ang II
has been implicated in this process [24-27]. To deter-
mine whether EndoMT could serve as a source of acti-
vated fibroblasts, we performed double-fluorescence
staining for VE-cadherin and FSP1 in the skin samples
from Ang II- and PBS-treated mice (Figure 7A). Ang
II-treated mice showed increased numbers of VE-cad-
herin/FSP1 double-positive cells distributed around
small vessels in the lower dermis. No VE-cadherin/
FSP1 double-positive cells were detected in the upper
dermis. In a complementary experiment, cultured
HDMECs treated with Ang II (Figure 7B) demon-
strated decreased expression of the endothelial marker,
VE-cadherin, and increased expression of the mesench-
ymal marker, FSP1.
Figure 4 Effect of angiotensin II on inflammation in mouse skin. (A) Real-time PCR analysis of CD3 and CD45/B220 in PBS- and Ang II-
treated mice (*P ≤ 0.05). (B) CD3 and CD45R staining on paraffin sections from PBS- and Ang II-infused mice. Representative images are shown
from four animals per group.
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Discussion
The renin-angiotensin system plays a key role in organ
fibrosis, including heart, kidney, lung, and liver [5,6,28,29].
In this study, we show that Ang II is also a potent inducer
of dermal fibrosis in a mouse model. Consistent with its
role in other organs, we provide the evidence that Ang II
induces dermal fibrosis through diverse pathogenic
mechanisms, including stimulation of collagen and CTGF
synthesis, myofibroblast differentiation, activation of M2
macrophages, recruitment of fibrocytes, and induction of
EndoMT.
Ang II infusion resulted in a dose-dependent deposition
of collagen in all dermal layers that was correlated with a
significant upregulation of interstitial collagen genes. Con-
sistent with other studies, we observed activation of the
TGF-b signaling pathway in response to Ang II treatment.
The interaction between Ang II and TGF-b in the context
of fibrosis is well characterized in many organs, including
kidney and heart [5,30]. Ang II is known to act both inde-
pendently and synergistically with TGF-b in promoting
excessive ECM production [5,30,31]. We also observed an
upregulation of CTGF, a well-known downstream media-
tor of the profibrotic effects of TGF-b [32]. Our data sug-
gest that activation of resident fibroblasts is the primary
mechanism responsible for extracellular matrix accumula-
tion. Consistent with this notion, we observed increased
numbers of FSP1-positive cells and increased numbers of
myofibroblasts, mainly throughout the upper dermis, sug-
gesting activation of resident fibroblasts, as well as their
differentiation to myofibroblasts. Ang II may act directly
on resident fibroblasts, as Ang II can upregulate both
aSMA and FSP1 in cultured dermal fibroblasts (Lukasz
Stawski and Maria Trojanowska, unpublished data). An
increased number of myofibroblasts, correlating with
increased expression of CTGF, was also observed in the
bleomycin-induced model of skin fibrosis [33].
Figure 5 Effect of angiotensin II on macrophage phenotype and localization in mouse skin. (A) Real-time PCR analysis of Emr1 in PBS-
and Ang II-treated mice (*P ≤ 0.05). (B) Mac3 and (C) CD163B staining on paraffin sections from PBS- and Ang II-infused mice. Arrows indicate
CD163-positive cells in the upper dermis. Representative images are shown from four animals per group.
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In renal and heart fibrosis models, Ang II contributes
to increased infiltration of immune cells by activating
the expression of the proinflammatory chemokine,
MCP1 [5]. Inflammation was also shown to be closely
associated with fibrosis in a bleomycin-induced model
of skin fibrosis [34]. Similarly, in our study, we
observed increased local infiltration of T cells, B cells,
and macrophages in the hypodermis of mouse skin,
which correlated with increased expression of MCP1 in
response to Ang II. Recruitment of inflammatory cells
by MCP1 plays an important role in skin fibrosis, as
MCP1-deficient mice showed reduced fibrosis com-
pared with WT mice in the bleomycin-induced skin
fibrosis model because of the decreased recruitment of
immune cells to the affected sites [35]. Importantly, we
observed an increased presence of CD163B-positive
cells representing a population of alternatively activated
M2 macrophages in the upper dermis of Ang II-infused
mice. Both classically activated macrophages (CAMs,
also called M1) and alternatively activated macrophages
(AAMs, also called M2) are known to play important
roles in wound repair and fibrosis, either by directly
releasing profibrotic cytokines or by recruiting other
cell types that regulate extracellular matrix turnover
[36]. In our study, M2 macrophages and myofibroblasts
showed similar distribution throughout the upper der-
mis, suggesting a potential contribution of M2 macro-
phages to myofibroblast differentiation. Interestingly,
colocalization of CD163B+ macrophages with aSMA+
myofibroblasts was recently demonstrated in the areas
of glomerular and interstitial fibrosis in a model of IgA
nephropathy [37]. Furthermore, CD163B+ macrophages
displayed strong staining for CTGF, suggesting produc-
tion of this profibrotic factor [37]. Activated M2
macrophages (CD163 positive) have also been found in
the skin of patients with localized scleroderma and
have been implicated as a possible source of profibrotic
cytokines [38].
Figure 6 Recruitment of fibrocytes after angiotensin II treatment. (A) Immunofluorescence staining of CD45 (red) and FSP1 (green) on
cryosections of skin samples from PBS- and Ang II-treated mice. Arrows indicate CD45/FSP1 and CD45/P4H double-positive cells. The bar graphs
represent quantification of percentage of total positive cells/HPF (high-power field) for CD45, FSP1, CD45/FSP1, and CD45/P4H in PBS- and Ang
II-treated mice (*P ≤ 0.05). Representative images are shown from four animals per group. (B) Real-time PCR for MCP1 and FSP1 in PBS (white
bars) and Ang II (black bars)-treated mice (*P ≤ 0.05).
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Accumulating evidence mainly from animal models of
organ fibrosis suggests that lesional myofibroblasts not
only may originate from resident fibroblasts, but also
may arise from circulating mesenchymal cells or from
endothelial cells through endothelial-to-mesenchymal
transitions. Fibrocytes have been implicated in the patho-
genesis of various experimental fibrotic conditions,
including bleomycin-induced pulmonary fibrosis [39],
renal fibrosis [40], liver fibrosis [41], and heart fibrosis
[42]. In our study, we showed an increased number of
infiltrating fibrocytes (CD45/FSP1 or CD45/P4H double-
positive cells) in the skin of Ang II-infused mice, which
may contribute to the development of fibrosis in
response to Ang II. In scleroderma, higher numbers of
cells described as “collagen-producing monocytes” was
observed in the peripheral blood of patients with intersti-
tial lung disease [43,44].
It was previously reported that Ang II plays an impor-
tant role in inducing EndoMT in early stages of cardiac
fibrosis [45]. Increased numbers of activated fibroblasts
originating from capillary endothelial cells also were
shown in a bleomycin-induced lung-fibrosis model [46].
Our results show increased number of cells co-expressing
the endothelial cell marker, VE-cadherin, and a mesenchy-
mal cell marker, FSP1, in Ang II-infused mouse skin,
suggesting increased EndoMT in response to Ang II.
However, we have observed the presence of such cells
only in the lower dermis, suggesting that they may have a
limited role in this model because the majority of myofi-
broblasts were present in the upper dermis. However,
determination of the precise contribution of the process of
EndoMT to this model of dermal fibrosis will require
reporter mice that would allow the lineage tracing of
endothelial cells. EndoMT is induced in response to
Figure 7 Effect of angiotensin II on EndoMT. Immunofluorescence staining of VE-cadherin (green) and FSP1 (red) in skin samples from PBS- and
Ang II-treated mice (left panel) and HDMECs treated with 1,000 ng/ml of Ang II and control (right panel). Arrows indicate Ve-cadherin/FSP1
double-positive cells. Representative images are shown from five animals per group.
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abnormal fibrillin-1 expression and chronic oxidative
stress in the Tsk+/- mouse, another model of SSc [47].
Conclusions
This work demonstrates that Ang II infusion induces
both inflammation and fibrosis in the skin via MCP1
upregulation and accumulation of activated fibroblasts.
Additionally, our data suggest that populations of these
fibroblasts originate from circulating blood cells. Ele-
vated serum levels of Ang II found in a subset of
patients with dcSS in the early stage of the disease sug-
gest that Ang II may contribute to the pathogenesis of
dcSSc, at least in a subset of patients [7]. The patho-
genic features observed in the Ang II model of dermal
fibrosis, such as infiltration of fibrocytes and a colocali-
zation of myofibroblasts with the M2 macrophages, are
particularly interesting, because they may help to eluci-
date similar processes occurring during the pathogenesis
of SSc. We believe that the Ang II model of dermal
fibrosis will be very useful for future mechanistic studies
of SSc pathogenesis and for the evaluation of novel anti-
fibrotic treatments.
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